Pulmonx Corporation (LUNG) Tops Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to Pulmonx Corporation (LUNG) Tops Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance

Pulmonx Reports First Quarter 2026 Financial Results

April 29, 2026 4:05 PM EDT

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.

Recent Highlights

Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first... More